阿斯利康旗下Koselugo获美国FDA批准用于成人Ⅰ型神经纤维瘤病治疗

环球市场播报
Nov 21, 2025

  阿斯利康公司周四宣布,美国食品药品监督管理局已批准口服MEK抑制剂Koselugo (selumetinib)用于治疗有症状、无法手术切除的丛状神经纤维瘤 (PN)的成人神经纤维瘤病1型 (NF1)患者。 该批准基于KOMET III期临床试验结果,该试验显示成人患者中肿瘤大小减少的总体响应率为20%。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10